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Huntington’s disease is an inherited neurodegenerative disease that causes motor, cognitive and psychiatric impairment, includ-
ing an early decline in ability to recognize emotional states in others. The pathophysiology underlying the earliest manifest-
ations of the disease is not fully understood; the objective of our study was to clarify this. We used functional magnetic
resonance imaging to investigate changes in brain mechanisms of emotion recognition in pre-manifest carriers of the abnormal
Huntington’s disease gene (subjects with pre-manifest Huntington’s disease): 16 subjects with pre-manifest Huntington’s dis-
ease and 14 control subjects underwent 1.5 tesla magnetic resonance scanning while viewing pictures of facial expressions from
the Ekman and Friesen series. Disgust, anger and happiness were chosen as emotions of interest. Disgust is the emotion in
which recognition deﬁcits have most commonly been detected in Huntington’s disease; anger is the emotion in which impaired
recognition was detected in the largest behavioural study of emotion recognition in pre-manifest Huntington’s disease to date;
and happiness is a positive emotion to contrast with disgust and anger. Ekman facial expressions were also used to quantify
emotion recognition accuracy outside the scanner and structural magnetic resonance imaging with voxel-based morphometry
was used to assess the relationship between emotion recognition accuracy and regional grey matter volume. Emotion processing
in pre-manifest Huntington’s disease was associated with reduced neural activity for all three emotions in partially separable
functional networks. Furthermore, the Huntington’s disease-associated modulation of disgust and happiness processing was
negatively correlated with genetic markers of pre-manifest disease progression in distributed, largely extrastriatal networks.
The modulated disgust network included insulae, cingulate cortices, pre- and postcentral gyri, precunei, cunei, bilateral puta-
mena, right pallidum, right thalamus, cerebellum, middle frontal, middle occipital, right superior and left inferior temporal gyri,
and left superior parietal lobule. The modulated happiness network included postcentral gyri, left caudate, right cingulate cortex,
right superior and inferior parietal lobules, and right superior frontal, middle temporal, middle occipital and precentral gyri.
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which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.These effects were not driven merely by striatal dysfunction. We did not ﬁnd equivalent associations between brain structure
and emotion recognition, and the pre-manifest Huntington’s disease cohort did not have a behavioural deﬁcit in out-of-scanner
emotion recognition relative to controls. In addition, we found increased neural activity in the pre-manifest subjects in response
to all three emotions in frontal regions, predominantly in the middle frontal gyri. Overall, these ﬁndings suggest that patho-
physiological effects of Huntington’s disease may precede the development of overt clinical symptoms and detectable cerebral
atrophy.
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Introduction
Huntington’s disease is a devastating inherited neurodegenerative
disease which causes motor, cognitive and psychiatric impairment.
This includes an early and salient decline in the ability to recognize
emotional states in others. However, the pathophysiology of emo-
tion processing in Huntington’s disease is not fully understood.
Improved understanding of emotion recognition difﬁculties will
contribute both to our understanding of Huntington’s disease
neurobiology, and to the design of symptomatic and disease-
modifying therapies. Emotion recognition in Huntington’s disease
has most frequently been studied by asking subjects to classify
pictures of facial expressions by emotion; reduced accuracy is
seen in both pre-manifest Huntington’s disease gene carriers and
patients with manifest disease. Speciﬁc ﬁndings have, however,
been variable, both in behavioural testing (Sprengelmeyer et al.,
1996, 2006; Gray et al., 1997; Wang et al., 2003; Hennenlotter
et al., 2004; Montagne et al., 2006; Johnson et al., 2007; Henley
et al., 2008; Aviezer et al., 2009; Tabrizi et al., 2009) and struc-
tural imaging studies (Johnson et al., 2007; Kipps et al., 2007;
Henley et al., 2008, 2011). There has been one previous func-
tional MRI study in which emotion perception was tested in
Huntington’s disease gene carriers: Hennenlotter and colleagues
(2004) showed nine subjects with pre-manifest Huntington’s dis-
ease and nine control subjects pictures of disgusted and surprised
(Ekman) faces. Small volume-corrected analyses carried out for
regions in the insulae and putamena (based on the results of pre-
vious studies in controls) revealed lower levels of blood oxygen
level-dependent (BOLD) signal in the left dorsal mid-anterior
insula in subjects with pre-manifest Huntington’s disease com-
pared with control subjects when they viewed disgusted faces.
This ﬁnding stimulated our study. We aimed to build on and
extend the functional MRI ﬁndings of Hennenlotter et al. (2004).
The study of emotion processing is of particular interest in
Huntington’s disease. From a clinical perspective, emotion process-
ing deﬁcits signal disease at an early stage (Johnson et al., 2007;
Tabrizi et al., 2009), while anecdotal accounts from the families of
those with Huntington’s disease suggest that impaired emotion
processing causes relationship breakdown and social isolation.
From a pathobiological perspective, emotional stimuli are likely
to probe a distributed cerebral network: emotion processing in
healthy controls activates widespread brain regions, including
the orbitofrontal cortex, amygdalae, basal ganglia and somato-
sensory cortex (Adolphs, 2001), while Huntington’s disease is
a whole-brain disease with early regional emphasis in the striatum
(Vonsattel et al., 1985; Aylward et al., 1994; Thieben et al., 2002;
Rosas et al., 2003; Paulsen et al., 2006; Tabrizi et al., 2009).
Neural dysfunction is thought to precede neuronal death and
brain atrophy; altered functional proﬁles during emotion recogni-
tion could provide a biomarker of disease evolution. Altered
extrastriatal neural activation has previously been detected in sub-
jects with pre-manifest Huntington’s disease (Hennenlotter et al.,
2004; Paulsen et al., 2004; Reading et al., 2004; Zimbelman
et al., 2007; Saft et al., 2008; Wolf et al., 2008; Kloppel et al.,
2009a, b).
In this study, we investigated changes in brain mechanisms
of emotion recognition in a cohort of subjects with pre-manifest
Huntington’s disease in order to open a window on Huntington’s
disease pathophysiology at the earliest stages of disease. Disgust,
anger and happiness were chosen as our emotions of interest for
the following reasons: disgust is the emotion in which recognition
deﬁcits have most commonly been detected across all modalities in
Huntington’s disease (Calder et al., 2010); anger is the emotion in
which a recognition deﬁcit was detected in the largest behavioural
study of emotion recognition in pre-manifest Huntington’s disease
to date (Johnson et al., 2007); and happiness is a positive valence
emotion, in contrast to disgust and anger. We used functional
MRI to test the hypothesis that emotion recognition in pre-
manifest Huntington’s disease is associated with altered neural
activation proﬁles compared with those of healthy controls. We
further hypothesized that this altered neural activation would be
more anatomically extensive than any disease-related structural
changes and would correlate with indices of Huntington’s disease
gene dosage (CAG repeat length and probability of manifest dis-
ease onset within ﬁve years). We used structural MRI with
voxel-based morphometry to assess the relationship between
emotion recognition accuracy and regional grey matter volume.
Materials and methods
Subjects
Sixteen subjects with pre-manifest Huntington’s disease (12 female;
age 31–65, mean 43.81 years) and 14 age-, sex- and education-
matched controls (10 female; age 24–62, mean 39.43 years) were
tested. The onset of manifest disease is deﬁned as the point at
which characteristic motor signs are seen (1996); our subjects did
1166 | Brain 2012: 135; 1165–1179 M. J. U. Novak et al.not show these signs. The study was approved by the Institute
of Neurology’s joint University College London/University College
London Hospital Trust ethics committee and written informed consent
was obtained from every subject. CAG repeat length, quantiﬁed
through genetic testing, ranged from 39 to 46 repeats in the subjects
with pre-manifest Huntington’s disease [mean 42, standard deviation
(SD) 1.89]. The CAG repeat length was used to estimate the probabil-
ity of manifest disease onset within the next 5 years for each individual
with pre-manifest Huntington’s disease (Langbehn et al., 2004). This
ranged from 0.03 to 0.62 (mean 0.26, SD 0.16). Both CAG repeat
length and probability of manifest disease onset within 5 years were
tested as they are different markers of Huntington’s disease gene
dosage: CAG repeat length is invariant from birth, and, as such, can
be seen as an overall measure of lifetime gene dosage. Calculation of
probability of manifest disease onset within 5 years takes account of
an individual’s age as well as their CAG repeat length, and therefore is
a marker of that individual’s gene dosage to date. Probability of mani-
fest disease onset within 5 years can therefore be viewed as a marker
of pre-manifest disease progression. Subject demographics are shown
in Table 1.
Genetic testing to exclude an expanded huntingtin gene was not
carried out in the control subjects for ethical reasons (genetic testing
has many emotional and practical implications) (Novak and Tabrizi,
2010), but none of the controls were at increased risk above the
very small risk in the general population of carrying an expanded
huntingtin gene.
Behavioural testing
All behavioural testing was carried out after scanning. Explicit recog-
nition of facial expressions of emotion was tested using the Ekman 60
faces test (Young et al., 2002) outside the scanner. Executive function
was tested using the European Huntington’s Disease Network short
cognitive battery, which comprises the Stroop task (Stroop, 1935),
Symbol-digit modalities test (Smith, 1968), Verbal ﬂuency test
(Borkowski, 1967) and Category ﬂuency test (Butters et al, 1987);
these are sensitive to cognitive decline in manifest Huntington’s dis-
ease. Premorbid intelligence was estimated using the National Adult
Reading Test (Nelson and Willison, 1991). Visual perception of facial
identity was tested using the Benton Facial Recognition Test (Benton
et al, 1983). Formal depression scores were not obtained, but all sub-
jects were tested and debriefed by a clinician with experience in
Huntington’s disease (M.J.U.N.); no signiﬁcant evidence of clinical
depression was detected.
Functional magnetic resonance
imaging task
During scanning, subjects viewed Ekman and Friesen pictures of facial
affect (Ekman et al., 1976) which had been cropped to remove hair
and facial outline. While viewing the faces, subjects carried out a dis-
tractor task of categorizing each face by gender with a button press;
implicit processing of facial expressions of emotion was therefore
tested in the scanner. A block design was used with the following
four block types: disgusted, angry, happy and neutral faces. Each
block consisted of 10 different faces showing the same facial expres-
sion. Each face was shown for 1s, with a 0.5–1.5s jitter between
them. Neutral faces were a morph of 75% neutral face and 25%
happy face [since 100% neutral faces are often perceived as adver-
sarial (Hennenlotter et al., 2004)]. Each block was shown four times;
there were 16 blocks in total, shown in pseudorandomized order.
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Emotion processing in pre-manifest Huntington’s disease Brain 2012: 135; 1165–1179 | 1167Brain image acquisition
Subjects were scanned on a Siemens 1.5T Sonata MRI scanner
(Siemens Medical Systems). Echo planar imaging data were acquired
during the functional MRI task using the following scanning
parameters: repetition time = 4.32s, slice repetition time = 90ms,
echo time = 50ms, ﬂip angle = 90, distance factor = 50%, voxel size
3  3  3mm (Weiskopf et al., 2006). Forty-eight slices of 2mm
thickness were acquired and the sequence was selected to achieve
optimal whole-brain coverage. The ﬁrst ﬁve ‘dummy’ volumes were
discarded to allow for T1 equilibration effects. Field inhomogeneity
maps were also acquired. A T1-weighted whole-brain structural
image was acquired for every subject with pre-manifest Huntington’s
disease and 13 of the controls. One hundred and seventy-six slices of
1mm thickness were acquired with the following parameters: repeti-
tion time = 20.66ms, echo time = 8.42ms, ﬂip angle = 25, slice thick-
ness = 1mm, 176 slices, voxel size 1  1  1mm (Deichmann, 2006).
General principles of data analysis
All data were ﬁrst analysed at a group level by comparing pre-manifest
Huntington’s disease and control data. Parametric analyses of the
pre-manifest Huntington’s disease data alone were then carried out
to assess relationships between functional changes and Huntington’s
disease metrics (CAG repeat length and probability of manifest disease
onset within 5 years).
Imaging data analysis
MRI data were processed using Statistical Parametric Mapping soft-
ware (SPM8; Wellcome Trust Centre for Neuroimaging http://www.ﬁl.
ion.ucl.ac.uk/spm) run on a MATLAB 7 R2010 platform (MathWorks).
Functional magnetic
resonance imaging data
Functional data were spatially realigned then corrected for inhomogen-
eity artefacts using the reconstructed ﬁeld maps. They were then regis-
tered to the standard Montreal Neurological Institute space using the
echo planar imaging template provided in SPM8, and ﬁnally smoothed
with a 10mm full-width half-maximum Gaussian kernel. Statistical
analysis was carried out using the general linear model (Friston
et al., 1995). Each block of data was modelled as a boxcar function
and convolved with the canonical haemodynamic response function
and its temporal derivative to create a regressor of interest. Four
regressors of no interest were modelled: button press times that fol-
lowed presentation of a stimulus, additional (erroneous) button press
times, stimulus presentation times of those trials where no button
response was made and the subject-speciﬁc movement parameters.
Three effects of interest were modelled in a common ﬁrst level
design matrix: each emotion regressor was compared with the neutral
regressor in the following contrasts: (disgust4neutral), (anger4neu-
tral) and (happiness4neutral).
Parameter estimates for these conditions were estimated at every
voxel for each subject and then entered into a second level random
effects analysis. A series of models was assessed at the second level to
explore the effects of potentially relevant disease-associated factors;
these models are summarized in Table 2.
Three models were initially created for each condition: two factorial
models to compare the control and pre-manifest Huntington’s disease
groups (Table 2, Models 1 and 2), and one regression model, which
contained data from the pre-manifest Huntington’s disease group only
(Table 2, Model 3). The ﬁrst factorial model contained no additional
regressors, whereas the second factorial model contained mean-
corrected CAG repeat length and probability of manifest disease
onset within ﬁve years respectively as regressors of ‘no interest’, or
‘nuisance covariates’. The second model therefore enabled us to test
for differences in mean activation levels between the pre-manifest
Huntington’s disease and control groups after controlling for hetero-
geneity in the pre-manifest Huntington’s disease data accounted for
by CAG repeat length and probability of manifest disease onset within
5 years. As there is no evidence that CAG repeat length modulates
behaviour at non-pathogenic repeat lengths, the controls were all
allotted CAG repeat length (and probability of manifest disease
onset within 5 years) values of zero, i.e. we used a constant regressor
to model the data with the assumption that variability in the control
data could not be attributed to CAG repeat length, in contrast to that
in the pre-manifest Huntington’s disease data. The pre-manifest
Huntington’s disease and control groups were matched for age and
sex; these were not therefore entered as regressors in between-group
comparisons. When pre-manifest Huntington’s disease data only were
included in the design matrix, age and sex were added as ‘nuisance
covariates’. Benton facial recognition score was added as a ‘nuisance
covariate’ in all models, in order to account for another relevant cog-
nitive capacity (face perception) that may have inﬂuenced facial emo-
tion processing. The pre-manifest Huntington’s disease regression
models contained CAG repeat length and probability of manifest dis-
ease onset within 5 years as additional regressors.
A second set of analyses was carried out to assess whether altered
extrastriatal activation in the pre-manifest Huntington’s disease group
was driven primarily by altered striatal activation (Table 2, Model 4).
A bilateral caudate/putamen/pallidum region of interest was deﬁned
using the WFU PickAtlas (Maldjian et al., 2003, 2004). For the
pre-manifest Huntington’s disease regression model that showed the
most anatomically extensive correlations (disgust4neutral), the mean
beta value (an index of BOLD activity) of voxels within the caudate/
Table 2 Details of functional MRI models
Model
number
Subject groups Covariates
1 Control and pre-manifest Huntington’s disease None
2 Control and pre-manifest Huntington’s disease CAG repeat length or probability of manifest disease onset within 5 years
3 Pre-manifest Huntington’s disease only CAG repeat length or probability of manifest disease onset within 5 years,
age, gender
4 Pre-manifest Huntington’s disease only Disgust only: mean striatal BOLD signal, age, gender
5 Control and pre-manifest Huntington’s disease Ekman 60 out-of-scanner score
1168 | Brain 2012: 135; 1165–1179 M. J. U. Novak et al.putamen/pallidum region of interest was calculated for each subject.
These mean striatal values were then re-entered into the correspond-
ing model as an additional regressor. A mask of the signiﬁcant voxels
from the original analysis was applied (voxels in which a signiﬁcant
inverse association between CAG repeat length and neural activity was
seen), and correlations between the mean striatal values and extra-
striatal activity were calculated in order to identify extrastriatal voxels
in which the BOLD signal covaried with the mean striatal BOLD signal.
Finally, a third set of analyses was carried out to assess the relation-
ship between the BOLD signal during emotion processing and accur-
acy scores from the previously described out-of-scanner Ekman 60
tests (Table 2, Model 5). These analyses were carried out to assess
differences between the pre-manifest Huntington’s disease and control
subjects in the extent to which anatomical associations of emotion
processing were related to the behavioural measure of emotion rec-
ognition by adding the Ekman 60 scores into the models for the cor-
responding emotion as regressors of interest.
Whole-brain analyses were carried out for every contrast. Results
are reported using set level signiﬁcance P50.05; set level signiﬁcance
was chosen because emotion recognition tasks and Huntington’s dis-
ease itself were predicted to produce changes in distributed neural
networks rather than in discrete brain regions (Friston et al., 1996).
Height threshold was set at P50.01; cluster size threshold at 520
voxels.
Debrieﬁng of our subjects after scanning revealed that all became
aware of the emotional content of the stimuli over the course of the
experiment. Additional post hoc analyses were therefore carried out to
compare BOLD levels in the ﬁrst blocks of the experiment (during
which most subjects were not yet aware of the emotion content)
with the BOLD levels in the ﬁnal blocks (during which all subjects
were aware that different blocks contained different emotional
stimuli).
Structural imaging data
Structural MRI data were ﬁrst partitioned into three tissue classes—
grey matter, white matter and CSF—using the ‘uniﬁed segmentation
approach’ in SPM8 (Ashburner and Friston, 2005). The grey matter
maps were registered to the standard Montreal Neurological Institute
space using Dartel, a diffeomorphic registration algorithm (Ashburner,
2007), adjusted for linear and non-linear effects of normalization
(i.e. ‘modulated’), and then smoothed with a 10mm full-width at
half-maximum Gaussian kernel. This produced smoothed modulated
normalized grey matter data which were statistically analysed using
a general linear model; this generated a voxelwise comparison of
local tissue volumes (Ashburner and Friston, 2000). General linear
models were also constructed to look for interactions between regional
grey matter volume and out-of-scanner Ekman 60 test scores in the
pre-manifest Huntington’s disease group versus controls. Total grey
matter volume was entered as an additional regressor in the design
matrix to control for variance in overall brain size so that regional grey
matter volume changes were identiﬁed. Whole-brain atrophy rates in
Huntington’s disease gene carriers are higher than those in controls
(Henley et al., 2009); by controlling for overall grey matter volume,
we therefore sought speciﬁcally to identify regional grey matter
volume loss over and above total grey matter volume loss. A
non-stationarity correction (Hayasaka et al., 2004) was used to correct
for non-uniformity in smoothness, allowing for the use of cluster-
based signiﬁcance values. Statistical parametric maps were thresholded
at the cluster level using family-wise error correction for multiple com-
parisons at P50.05.
As in the functional MRI analyses, age and sex were not entered
as regressors in between-group comparisons, but were included
in pre-manifest Huntington’s disease-only analyses. Separate
pre-manifest Huntington’s disease models were constructed with
CAG repeat length and probability of manifest disease onset within
5 years as regressors of interest to test their relationship with regional
grey matter volume. Whole-brain structural analyses were followed by
region of interest analyses; the regions of interest were based on prior
anatomical hypotheses concerning the brain substrates for emotion
processing and the evolution of atrophy in Huntington’s disease, and
were deﬁned using the WFU PickAtlas (Maldjian et al., 2003, 2004).
These regions of interest were combined and used to reduce the
search volume to caudate, putamen, pallidum, insula, amygdala, som-
atosensory cortex and orbitofrontal cortex by applying small volume
correction (Worsley et al., 1996). In addition, a bilateral caudate/pu-
tamen/pallidum-only region of interest was used for those analyses
not involving emotion data; the regions were chosen to reﬂect the
predominance of early structural Huntington’s disease changes in
these nuclei.
Results
Behavioural data
Out-of-scanner behavioural data are summarized in Table 1
(a breakdown of the results for individual subjects is available
from the authors on request). The pre-manifest Huntington’s dis-
ease and healthy control groups did not differ in accuracy for
recognition of disgust, anger or happiness (happiness recognition
was near ceiling level across both groups), whether or not CAG
repeat length and probability of manifest disease onset within
5 years were adjusted for (ANCOVA, P40.05). Scores in the
group with pre-manifest Huntington’s disease were normally dis-
tributed only for disgust recognition (Kolmogorov-Smirnov test,
P40.05), so Spearman’s correlation coefﬁcient (one-tailed) was
used to assess correlations between Ekman scores and CAG repeat
length and probability of manifest disease onset within 5 years. In
the pre-manifest Huntington’s disease group, accuracy of disgust
recognition was found to correlate inversely with CAG repeat
length (Spearman’s correlation coefﬁcient = 0.635), and accur-
acy of anger recognition inversely with CAG repeat length
(Spearman’s correlation coefﬁcient = 0.466) and probability of
manifest disease onset within 5 years (Spearman’s correlation
coefﬁcient = 0.529) (P50.05). There was no difference in
task performance between the groups on the European
Huntington’s Disease Network short cognitive battery, the
National Adult Reading Test or the Benton facial recognition
test. Subjects with pre-manifest Huntington’s disease had signiﬁ-
cantly higher scores than controls on the Uniﬁed Huntington’s
Disease Rating Scale motor score (P=0.02; pre-Huntington’s dis-
ease score range = 0–24; control score range = 0–2); the effects of
subtle motor impairment in the subjects with pre-manifest
Huntington’s disease were controlled for in the functional MRI
analyses by including button press times (i.e. reaction times) as
regressors in the ﬁrst level models.
Emotion processing in pre-manifest Huntington’s disease Brain 2012: 135; 1165–1179 | 1169Functional magnetic resonance
imaging data
Functional MRI results are reported in three sections: (i) and (ii)
analyses using models that contained no data about out-of-
scanner emotion recognition accuracy (Table 2, Models 1–4;
showing the neural substrates of emotion processing in pre-
manifest Huntington’s disease) and (iii) analyses using models
that included a regressor containing the Ekman 60 recognition
score for the corresponding emotion (Table 2, Model 5; showing
the relationship between neural activity and behaviour on the
out-of-scanner Ekman 60 test). Results are reported with set
level signiﬁcance P50.05. Regional anatomical data are summar-
ized in Table 3; statistical parametric maps are displayed overlaid
on a mean structural image in Figs 1 and 2 and Supplementary
Figs 4–6. In the post hoc analyses investigating systematic alter-
ations in BOLD response over time in the scanner (i.e. BOLD ef-
fects potentially associated with a qualitatively altered mode of
cognitive processing of the emotion stimuli over the course of
the experiment), no trends were seen.
(i) Models testing for differences in activation between the
pre-manifest Huntington’s disease and control groups (not
including the Ekman 60 regressor)
After adjusting for variance in the pre-manifest Huntington’s
disease group attributable to gene dosage by adding CAG
repeat length and probability of manifest disease onset within 5
years respectively as ‘nuisance variables’ (Table 2, Model 2), ex-
tensive regions were found in which controls had greater activa-
tion than the pre-manifest Huntington’s disease group in all three
emotion contrasts: the disgust4neutral condition (with CAG
repeat length correction, P51  10
10; nine clusters; with prob-
ability of manifest disease onset within 5 years correction,
P51  10
10; 17 clusters), the anger4neutral condition (with
CAG repeat length correction, P51  10
10; nine clusters; with
probability of manifest disease onset within 5 years correction,
P51  10
10; seven clusters), and the happiness4neutral con-
dition (with CAG repeat length correction, P51  10
10; 11 clus-
ters; with probability of manifest disease onset within 5 years
correction, P51  10
10; 12 clusters).
The network of decreased activation identiﬁed in the dis-
gust4neutral contrast after CAG repeat length adjustment
included right middle frontal gyrus, left precentral gyrus, right
postcentral gyrus, bilateral paracentral lobules, left anterior and
mid-insula, left superior and inferior parietal lobules and right pos-
terior cingulate cortex. Similar results were seen with probability of
manifest disease onset within 5 years replacing CAG repeat length
in the model (Table 2, Model 2).
The network of decreased activation identiﬁed in the
anger4neutral contrast after CAG repeat length adjustment
included right caudate, left paracentral lobule, bilateral anterior
and mid-insulae, bilateral hippocampi, left middle occipital gyrus
and right mid-cingulate cortex (Table 2, Model 2). Similar results
were seen with probability of manifest disease onset within 5 years
replacing CAG repeat length in the model.
The network of decreased activation identiﬁed in the hap-
piness4neutral contrast after CAG repeat length correction
included bilateral caudates, left precuneus, right anterior and
mid-insula, left hippocampus, left cuneus, bilateral middle occipital
gyri and bilateral anterior cingulate cortex. Similar results were
seen with probability of manifest disease onset within 5 years
replacing CAG repeat length in the model (Table 2, Model 2).
After adjusting for variance in the pre-manifest Huntington’s
disease group attributable to gene dosage (Table 2, Model 2),
regions were also found in which the subjects with pre-manifest
Huntington’s disease had greater activation than the controls in
the disgust4neutral (with CAG repeat length correction,
P=4.4  10
5; three clusters) and anger4neutral (with CAG
repeat length correction, P51  10
10; six clusters) contrasts.
Similar results were seen with probability of manifest disease
onset within 5 years replacing CAG repeat length in the
model. Regions in which the subjects with pre-manifest
Huntington’s disease had greater activation than the controls
were seen in the happiness4neutral contrast after adjusting for
probability of manifest disease onset within 5 years
(P=4.0  10
5; three clusters); the effect was not seen after ad-
justing for CAG repeat length.
The network of increased activation in the subjects with pre-
manifest Huntington’s disease identiﬁed in the disgust4neutral
contrast after CAG repeat length adjustment included bilateral
middle frontal gyri and right pallidum.
The network of increased activation in the subjects with
pre-manifest Huntington’s disease identiﬁed in the anger4neutral
contrast after CAG repeat length adjustment included right super-
ior and left inferior frontal gyri, bilateral anterior cingulate cortex,
left isthmus, right pons and right cerebellum.
The network of increased activation in the subjects with
pre-manifest Huntington’s disease identiﬁed in the
happiness4neutral contrast after probability of manifest disease
onset within 5 years adjustment included bilateral middle frontal
gyri and left anterior cingulate cortex.
Activations did not differ signiﬁcantly between the pre-manifest
Huntington’s disease and healthy control groups when CAG
repeat length/probability of manifest disease onset within
5 years-related heterogeneity in the pre-manifest Huntington’s
disease group was not corrected for (Table 2, Model 1).
The beta values for all subjects (controls and pre-manifest
Huntington’s disease) in the disgust4neutral condition at a
sample of voxels in which reduced mean BOLD signal was seen
in the subjects with pre-manifest Huntington’s disease are shown
plotted against CAG repeat length and probability of manifest
disease onset within 5 years in Fig. 3: this demonstrates the dis-
tribution of the mean BOLD signal across both subject groups, and
the associations with CAG repeat length and probability of mani-
fest disease onset within 5 years in the pre-manifest Huntington’s
disease group, illustrating how these associations account for a
signiﬁcant level of variance.
(ii) Models testing for modulation in pre-manifest Huntington’s
disease activation by gene dosage (not including Ekman 60
regressor)
For the disgust4neutral contrast in the pre-manifest
Huntington’s disease group, both CAG repeat length and prob-
ability of manifest disease onset within 5 years covariates were
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Emotion processing in pre-manifest Huntington’s disease Brain 2012: 135; 1165–1179 | 1171Figure 1 Statistical parametric maps showing the regions in which BOLD signal is lower in subjects with pre-manifest Huntington’s
disease than in controls after controlling for CAG repeat length in the following conditions: (A) disgust4neutral; (B) anger4neutral; and
(C) happiness4neutral. P = posterior; A = anterior; L = left; R = right.
1172 | Brain 2012: 135; 1165–1179 M. J. U. Novak et al.inversely correlated with activation of an extensive network
including bilateral anterior and mid-insulae and bilateral anterior
and right mid-cingulate cortices, right middle frontal and middle
occipital gyri, putamen, pallidum and anterior lobe of the cerebel-
lum, and left precuneus, superior parietal lobule and pre- and
postcentral gyri. CAG repeat length was additionally inversely cor-
related with activation of the right precuneus, precentral gyrus and
thalamus, and left middle occipital gyrus and putamen. Probability
of manifest disease onset within 5 years was additionally inversely
correlated with activation of the left middle frontal gyrus,
right superior and left inferior temporal gyri, right superior occipital
gyrus, left angular gyrus, right inferior parietal lobule, bilateral
cunei, and left mid- and right posterior cingulate cortices
(Table 2, Model 3; Fig. 2).
Figure 2 Statistical parametric maps showing the negative correlations between pre-manifest HD levels of BOLD in the disgust4neutral
condition and: (A) CAG repeat length and (B) probability of manifest disease onset within ﬁve years. (C) shows the two sets of negative
correlations on the same image: negative correlations with CAG repeat length are shown in yellow and negative correlations with
probability of manifest disease onset within ﬁve years are shown in blue. Overlapping regions are shown in green. P = posterior;
A = anterior; L = left; R = right.
Emotion processing in pre-manifest Huntington’s disease Brain 2012: 135; 1165–1179 | 1173Figure 3 Plots of the normalized mean BOLD signal for each subject in the disgust4neutral contrast against CAG repeat length repeat
length (left) and probability of disease onset in 5 years (right). Black circles represent subjects with pre-manifest Huntington’s disease and
white diamonds represent controls. Controls are plotted against a CAG repeat length repeat length of 18 based on a previous study
showing a mean CAG repeat length repeat length of 18 in 360 controls (Snell et al., 1993), and a probability of manifest disease onset
within 5 years of 0. PDO = probability of disease onset within 5 years.
1174 | Brain 2012: 135; 1165–1179 M. J. U. Novak et al.For the happiness4neutral contrast in the pre-manifest
Huntington’s disease group, both the CAG repeat length and
probability of manifest disease onset within 5 years covariates
were inversely correlated with activation in the right superior fron-
tal gyrus, right postcentral gyrus, right anterior insula, right middle
occipital gyrus and right mid-cingulate cortex. CAG repeat length
was additionally inversely correlated with activation of left post-
central gyrus and right mid-insula. Probability of manifest disease
onset within 5 years was additionally inversely correlated with
activation of the left caudate, right precentral gyrus, right superior
and inferior parietal lobules and right middle temporal gyrus.
There were no signiﬁcant correlations between CAG repeat
length or probability of manifest disease onset within 5 years
and BOLD level in the anger4neutral contrast.
We carried out further analyses to establish whether the pre-
dominantly extrastriatal correlations seen in the pre-manifest
Huntington’s disease group in the disgust4neutral contrast
were driven by altered striatal activity. This contrast was chosen
for additional analyses because the network it revealed was the
most anatomically extensive of all our results. Mean BOLD signal
within the striatal subregion covaried with neuronal activity in
extrastriatal areas in the disgust4neutral contrast, including
voxels within the right pre-and postcentral gyri, left middle frontal
gyrus, right inferior parietal lobule, bilateral precunei and cunei,
right operculum, left inferior temporal gyrus, left lingual gyrus, left
middle occipital gyrus, right anterior cingulate gyrus and left an-
terior lobe of the cerebellum (Table 2, Model 4; Supplementary
Fig. 5). However, this covariance between striatal and extrastriatal
areas was not uniform: covariation was not observed in the
anterior insulae, right mid-insula, left anterior or right mid-
cingulate cortices, right middle frontal gyrus, right middle occipital
gyrus, right anterior lobe of the cerebellum, left superior parietal
lobule or left pre- or postcentral gyri.
(iii) Models testing for differences in activation between the pre-
manifest Huntington’s disease and control groups and including
the Ekman 60 regressor
The activation proﬁle in the disgust4neutral contrast had a
stronger positive correlation with out-of-scanner disgust recogni-
tion performance in the pre-manifest Huntington’s disease group
than in healthy controls: this activation proﬁle comprised distrib-
uted bihemispheric areas including mid-insulae and precentral gyri,
as well as left putamen, left middle frontal gyrus, right postcentral
gyrus, right superior parietal lobule, right superior temporal
gyrus, left lingual gyrus, left anterior cingulate cortex and right
anterior lobe of the cerebellum (P51  10
10; 14 clusters;
Table 2, Model 5; Supplementary Fig. 6). The areas showing
this correlation partly overlapped those areas (described in the
section above) in which there was a negative correlation with
CAG repeat length and probability of manifest disease onset
within 5 years in the pre-manifest Huntington’s disease group in
the disgust4neutral contrast (Fig. 2).
The activation proﬁle in the anger4neutral contrast had a
stronger positive correlation with out-of-scanner anger recognition
performance in the pre-manifest Huntington’s disease group than
in healthy controls in the right superior frontal gyrus, and left
middle frontal and postcentral gyri (P=3.7  10
5; three clusters;
Table 2, Model 5). The activation proﬁle had a stronger positive
correlation with out-of-scanner anger recognition performance in
the healthy controls in the left pallidum, left precuneus, right
middle and left inferior occipital gyri (P51  10
10; six clusters;
Table 2, Model 5).
These analyses were not carried out for the happiness4neutral
condition because performance in the Ekman test for happiness
recognition was at ceiling level for most subjects.
Structural: voxel-based morphometry
Voxel-based morphometry results are shown in Supplementary
Table 4. On whole-brain analysis, the pre-manifest Huntington’s
disease group had lower grey matter volume than the control
group in the caudate head and putamen bilaterally (right
P=0.022; left P=0.028) and in the left occipital lobe
(P=0.033). No regions of higher grey matter volume were
found in the pre-manifest Huntington’s disease group compared
with controls. Within the pre-manifest Huntington’s disease group,
grey matter volume in the caudate and putamen was negatively
correlated with CAG repeat length (small volume-corrected with
bilateral caudate/putamen/pallidum region of interest, P 4 0.01;
correlation with grey matter volume in left caudate and putamen
only on whole-brain analyses, P=0.007); and with probability of
manifest disease onset within 5 years (whole-brain analysis, P 4
0.03) (Supplementary Fig. 7). Within the reduced search volume
deﬁned by the bilateral caudate/putamen/pallidum/insula/amyg-
dala/somatosensory cortex/orbital frontal cortex mask, grey
matter volume in the left precentral gyrus, left middle frontal
and right superior frontal gyri was negatively correlated with
CAG repeat length, and grey matter volume in the left caudate
head and putamen and right middle frontal gyrus was negatively
correlated with probability of manifest disease onset within
5 years. There was no evidence for the reverse associations.
No signiﬁcant interactions between subject group, grey matter
volume and out-of-scanner emotion recognition performance
were found for out-of-scanner disgust or anger recognition per-
formance, irrespective of whether CAG repeat length and prob-
ability of manifest disease onset within 5 years were included
as ‘nuisance covariates’ (happiness was not evaluated because
performance was at ceiling for most subjects).
Discussion
Here we have shown that viewing facial expressions of anger,
disgust or happiness is associated with altered levels of neural
activation in individuals with pre-manifest Huntington’s disease
in comparison with healthy control subjects. In the subjects with
pre-manifest Huntington’s disease, signiﬁcantly lower levels of
neural activation were present in a distributed brain network;
more anatomically limited regions of increased activation were
present, primarily in the frontal lobes. Huntington’s disease-
associated activation differences were not restricted to a particular
emotional expression or emotion valence. Furthermore, this differ-
ential activation proﬁle varied amongst individual subjects with
pre-manifest Huntington’s disease and was observed only after
Emotion processing in pre-manifest Huntington’s disease Brain 2012: 135; 1165–1179 | 1175controlling for effects from Huntington’s disease genotype (CAG
repeat length repeat length/probability of manifest disease onset
within 5 years). Huntington’s disease, including pre-manifest
Huntington’s disease, appears to be a remarkably heterogeneous
condition with extensive variation in phenotype between indi-
viduals. It is therefore perhaps unsurprising that (i) we found
extensive variation in neural activity within the pre-manifest
Huntington’s disease group; and that (ii) the differential activation
between the subjects with pre-manifest Huntington’s disease and
controls was only seen once the variance associated with CAG
repeat length/probability of disease onset within 5 years was
explicitly modelled. The overall relationship in the pre-manifest
Huntington’s disease group between Huntington’s disease gene
status and neural activity was complex. Differential activation rela-
tive to controls occurred independently of gene dosage during
processing of all three tested emotions, arguing for a baseline
alteration in neural activity conferred by the expanded
Huntington’s disease gene; however, associations between gene
dosage (CAG repeat length/probability of manifest disease onset
within 5 years) and BOLD signal were also seen, suggesting a
genetic dose-dependent reduction in neural activity. Previous
functional MRI studies (Paulsen et al., 2004; Wolf et al., 2007;
Zimbelman et al., 2007; Saft et al., 2008; Kloppel et al., 2009a)
have shown that pre-manifest Huntington’s disease gene carriers
relative to healthy controls exhibit either an overall increase in
BOLD signal or an ‘inverted U’-like pattern of change over time.
Considered in conjunction with this previous work, our ﬁndings
suggest that the proﬁle of Huntington’s disease-associated
changes in BOLD signal may be speciﬁc to a particular cognitive
process or may follow a different time course for different cogni-
tive functions.
Negative correlations were observed here in the pre-manifest
Huntington’s disease group between striatal and extrastriatal
regional BOLD signal, and between BOLD signal, Huntington’s
disease gene status and CAG repeat length and probability of
manifest disease onset within 5 years in widespread cortical
areas. The covariance of striatal and extrastriatal activity was not
uniform across brain regions; this suggests that the modulation of
extrastriatal activity is not entirely driven by modulation of striatal
activity. Positive correlations between BOLD signal, Huntington’s
disease gene status and CAG repeat length and probability of
manifest disease onset within 5 years were observed in a more
anatomically limited distribution—most consistently in the superior
and middle frontal gyri—suggesting a predominantly frontal, com-
pensatory network. Huntington’s disease-associated functional
changes were more anatomically extensive than structural
(voxel-based morphometry) changes: while indirect comparisons
of the statistical inferences drawn from separate models of differ-
ent imaging modalities must be cautious, the present ﬁndings sug-
gest that altered extrastriatal function occurs at an early stage in
the pathogenesis of Huntington’s disease and in the absence of
detectable equivalent extrastriatal volume loss. The ﬁnding of
modulated neural activity in widespread brain regions extends
the previous observation of reduced insula activation using a simi-
lar functional MRI paradigm (Hennenlotter et al., 2004), perhaps
reﬂecting our larger subject cohort with enhanced power to carry
out less anatomically constrained analyses. Three structural
imaging studies to date have assessed the relationship between
regional brain volumes and accuracy of explicit classiﬁcation of
facial expressions of emotion in Huntington’s disease. The largest
of these found no correlation between emotion recognition per-
formance and caudate volumes (Johnson et al., 2007), while cor-
relations have been shown with regional grey matter volume in
other brain areas, including anteroventral insula (disgust) (Kipps
et al., 2007), amygdala (happiness) (Kipps et al., 2007) and stri-
atum (anger) (Henley et al., 2008). Allowing for the important
caveats of methodological variation and intrinsic biological hetero-
geneity, our ﬁndings suggest a potential unifying explanation for
these apparent disparities in previous work: Huntington’s disease
modulates activity across a predominantly extrastriatal but distrib-
uted emotion processing network.
Considerable interest in the literature on clinical Huntington’s
disease has centred on the speciﬁcity of deﬁcits for the processing
of particular emotions; no deﬁnitive synthesis has emerged
(Henley et al., 2011). Huntington’s disease-associated variability
in emotion processing is in keeping with the marked heterogeneity
of Huntington’s disease symptom expression in general: study of
emotion processing in Huntington’s disease is therefore a useful
window onto the phenotypical heterogeneity of the disease. In the
present study, individual emotions were associated with separable
proﬁles of functional alteration, suggesting that the mechanism of
Huntington’s disease-associated modulation may be at least partly
emotion-speciﬁc. Facial expressions of positive emotion (i.e. hap-
piness) are intrinsically easier to recognize than negative emotions,
at least using conventional emotion stimuli; a smile is both highly
distinctive and pathognomonic of happiness (Adolphs, 2002),
whereas negative emotions (such as anger and disgust) rely on
more ﬁne-grained encoding across a broader range of distinctive
emotion categories. Healthy subjects typically perform at ceiling
level for recognition of happy facial expressions and, indeed, after
accounting for this, a behavioural impairment in the recognition of
happy facial expressions has not been reported in pre-manifest
Huntington’s disease. In the present study, we have shown that
functional responses to expressions of happiness as well as nega-
tive emotions (anger and disgust) are altered in pre-manifest
Huntington’s disease despite a level of out-of-scanner recogni-
tion accuracy comparable to healthy individuals. These ﬁndings
suggest that functional MRI indices may be more sensitive than
behavioural indices in tracking altered emotion processing in
Huntington’s disease, and raise the further possibility that the
use of alternative, more ﬁnely differentiated stimuli might however
reveal hitherto largely undetected deﬁcits in processing
positive-valence facial expressions. The detection of impaired rec-
ognition of vocal expressions of positive emotions in Huntington’s
disease in one previous study (Robotham et al., 2011) supports
this assertion.
In the present task we sought to minimize the requirement for
in-scanner explicit recognition or labelling of particular emotions as
this is one potential source of discrepancy between past studies of
emotion processing in Huntington’s disease (Snowden et al.,
2008). Although debrieﬁng of our subjects revealed that all
became aware of the emotional content of the stimuli, this was
not reﬂected in any systematic trend in BOLD response. It is there-
fore unlikely that the differential associations we observed in
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of facial emotions. Rather, we argue that these Huntington’s
disease-associated activation changes reﬂect altered brain mech-
anisms intrinsic to the processing of emotional stimuli: differential
neural associations for the processing of particular emotions could
arise if (as is likely) the pathological process in Huntington’s dis-
ease affects the brain substrates for processing particular emotions
non-uniformly as the disease develops. The inclusion of individuals
at different stages of disease evolution is a potential source of
discrepancy between this and other studies of emotion processing
in Huntington’s disease (Snowden et al., 2008; Henley et al.,
2011), and the variance in our functional MRI data underlines
the importance of considering this factor.
Our results suggest that a distributed cortico-striatal network
modulates the processing of emotional stimuli in pre-manifest
Huntington’s disease. There are several possible mechanisms that
could mediate this modulatory effect. The insula has been impli-
cated previously as a key region associated with disgust processing
(Phillips et al., 1997; Wicker et al., 2003, Harrison et al., 2010);
though the precise role of this area remains unclear, it may facili-
tate emotion imagery or the processing of emotion under condi-
tions of increased cognitive load (Phan et al., 2002). The
somatosensory cortices have also been implicated in emotion rec-
ognition (Adolphs et al., 2000; Banissy et al., 2010) and may at
least partly facilitate understanding of the emotional states of
others via a mimicry process (Adolphs et al., 2000). Impaired abil-
ity to internalize an observed emotional state through disordered
somatosensory representations might plausibly accompany the
evolving disease process in Huntington’s disease. The precuneus
has also been implicated in emotion recognition (Ochsner et al.,
2004); however, it has also consistently been shown to be active
in resting state functional MRI studies. Resting state studies reveal
the ‘default mode network’: those regions of the brain implicated
in mind-wandering, or day-dreaming (Mason et al., 2007).
Modulation of activity of these ‘default mode’ areas in this
study might indicate that increased neural resources are directed
toward emotion processing (i.e. the processing of salient external
stimuli) as pre-manifest Huntington’s disease subjects approach
disease onset and inhibit day-dreaming to focus attention on the
task. The middle frontal gyri, in which we detected increased
neural activity in our subjects with pre-manifest Huntington’s dis-
ease, are often activated in tasks requiring executive functions,
such as response inhibition (Blasi et al., 2006) and attentional
control (Corbetta and Shulman, 2002). A compensatory increase
in executive processing of affective stimuli is a credible mechanism
by which normal emotion recognition ability might be retained in
the face of reduced neural activity in other emotion processing
brain regions in pre-manifest Huntington’s disease.
This study has demonstrated modulation of a large-scale, pre-
dominantly extrastriatal functional brain network in association
with the processing of positive and negative emotions in
pre-manifest Huntington’s disease gene-carriers compared with
healthy control subjects. Neural activation during emotion process-
ing was associated with metrics of Huntington’s disease gene
dosage. These functional alterations in the pre-manifest
Huntington’s disease cohort were not reﬂected in an overall be-
havioural deﬁcit in out-of-scanner emotion recognition, nor
modiﬁed substantially by incorporation of emotion recognition
performance as a regressor in the BOLD analysis; behavioural
interpretations of the functional MRI ﬁndings must, therefore, be
cautious. There was, however, evidence for increased strength of
association between neural activation and recognition perform-
ance in the pre-manifest Huntington’s disease group compared
with controls, and for modulation of emotion recognition perform-
ance by gene dosage. These ﬁndings strongly suggest that the
functional alterations identiﬁed here are behaviourally relevant.
The functional alterations extended widely beyond the region of
structural brain atrophy; furthermore, structural associations of
emotion processing were not identiﬁed in this pre-manifest
Huntington’s disease cohort. Taken together, the present ﬁndings
suggest that pathophysiological metrics of emotion processing
may have a role as biomarkers of early (pre-manifest)
Huntington’s disease, particularly in the assessment of extrastriatal
dysfunction. The results further suggest that metrics of extrastria-
tal function should be pursued and exploited in designing and
assessing new symptomatic and disease-modifying therapies in
Huntington’s disease. Quantiﬁcation of resting state regional cere-
bral blood ﬂow has recently been proposed as a biomarker in
Huntington’s disease (Wolf et al., 2011); future longitudinal stu-
dies could helpfully explore the potential of task-based functional
MRI to complement resting state data. Key directions for future
work will include the detailed longitudinal tracking of functional
in relation to structural and behavioural change in Huntington’s
disease (including studies expressed designed to compare the
sensitivity of structural and functional imaging modalities), and
assessment of a wider range of emotional stimuli and relevant
in-scanner behavioural tasks.
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